Reports of the application of FoundationOne and FoundationOne Heme assays in clinical practice are growing in the scientific literature. Therefore I have assembled this special edition of the BiotechDueDIligence Journal Watch to highlights a number of recent publications related to FMI.
Genomics-based early-phase clinical trials in oncology: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.
Sclerosing epithelioid fibrosarcoma presenting as intraabdominal sarcomatosis with a novel EWSR1-CREB3L1 gene fusion
Theranostic Profiling for Actionable Aberrations in Advanced High Risk Osteosarcoma with Aggressive Biology Reveals High Molecular Diversity: The Human Fingerprint Hypothesis
Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies
Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer
Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy
Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing
PubMed search results with >20 additional, older publications related to Foundation Medicine $FMI